CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended		207 Months Ended
	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013
Cash Flows From Operating Activities:
Net loss	$ (6,297,184)	$ (8,782,297)	$ (360,470,744)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	234,603	320,127	10,143,143
Minority Interest Share of Loss	0	0	(3,038,185)
Reduction of notes receivable - common stock in exchange for services rendered	0	0	423,882
Write-off of uncollectible notes receivable - common stock	0	0	391,103
Write-off of deferred offering costs	0	0	3,406,196
Write-off of abandoned patents	0	88,582	1,353,976
Gain on disposal of property and equipment	(993,867)	(726,464)	(2,985,017)
Loss on extinguishment of debt	0	0	14,134,068
Common stock issued as employee compensation	0	11,783	4,011,938
Amortization of options and option modifications as stock compensation	19,697	44,415	3,430,923
Common stock issued for services rendered	185,342	393,145	14,692,621
Amortization of prepaid services in conjunction with common stock issuance	0	0	138,375
Non-cash compensation expense	0	0	45,390
Stock options and warrants issued for services rendered	0	0	7,956,723
Issuance of warrants as additional exercise right inducement	0	0	21,437,909
Preferred stock issued for services rendered	0	0	100
Treasury stock redeemed for non-performance of services	0	0	(138,000)
Amortization of deferred debt issuance costs and loan origination fees	0	0	2,405,629
Amortization of discount on convertible debentures	0	0	38,345,592
Common stock issued for interest on convertible debentures & preferred stock	604,800	347,490	1,847,504
Interest on short-term advance	0	0	22,190
Founders' shares transferred for services rendered	0	0	353,506
Fees in connection with refinancing of debt	0	0	113,274
Warrant repricing costs	0	0	3,198,604
Change in fair value of derivative liabilities	3,783,290	4,212,545	4,499,267	[1]
Changes in operating assets and liabilities (excluding the effects of acquisition):
Accounts receivable	0	8,472	(15,047)
Miscellaneous receivables	0	0	43,812
Inventory	0	215,834	(20,091)
Other current assets	39,179	(116,509)	(143,769)
Accounts payable and accrued expenses	449,789	(617,777)	15,473,729
Deferred revenue	(25,300)	(11,426)	232,032
Other, net	0	0	110,317
Net Cash Used in Operating Activities	(1,999,651)	(4,612,080)	(218,599,049)
Cash Flows From Investing Activities:
Purchase of property and equipment	0	(2,416)	(4,809,439)
Proceeds from sale of property and equipment	1,578,779	1,788,554	6,532,104
Costs incurred for patents	(40,234)	(82,530)	(2,880,280)
Change in restricted cash	0	0	512,539
Proceeds from maturity of short-term investments	0	0	195,242,918
Purchases of short-term investments	0	0	(195,242,918)
Cash received in conjunction with merger	0	0	82,232
Advances to Antigen Express, Inc.	0	0	(32,000)
Increase in officers' loans receivable	0	0	(1,126,157)
Change in deposits	0	0	(652,071)
Change in notes receivable - common stock	0	0	(91,103)
Change in due from related parties	0	0	(2,222,390)
Other, net	0	0	89,683
Net Cash Provided by/(Used in) Investing Activities	1,538,545	1,703,608	(4,596,882)
Cash Flows From Financing Activities:
Proceeds from short-term advance	0	0	325,179
Repayment of short-term advance	0	0	(347,369)
Proceeds from issuance of long-term debt	866,403	1,351,472	6,433,700
Repayment of long-term debt	(1,692,957)	(701,363)	(8,755,656)
Repayment of obligations under capital lease	0	0	(83,002)
Change in due to related parties	0	0	154,541
Proceeds from exercise of warrants	724,664	30,000	46,452,945
Proceeds from exercise of stock options	86	0	5,003,879
Proceeds from minority interest investment	0	0	3,038,185
Proceeds from issuance of preferred stock	1,450,000	0	17,755,000
Redemption of SVR preferred stock	0	0	(100)
Proceeds from issuance of convertible debentures, net	0	0	40,704,930
Payment of costs associated with convertible debentures	0	0	(722,750)
Repayments of convertible debentures	0	0	(5,142,424)
Purchase of treasury stock	0	0	(483,869)
Proceeds from issuance of common stock, net	0	0	120,576,242
Purchase and retirement of common stock	0	0	(497,522)
Net Cash Provided by Financing Activities	1,348,196	680,109	224,411,909
Effect of Exchange Rates on Cash	(10,687)	(25,657)	(93,266)
Net Increase/(Decrease) in Cash and Cash Equivalents	876,403	(2,254,020)	1,122,712
Cash and Cash Equivalents, Beginning of Period	246,309	2,798,797	0
Cash and Cash Equivalents, End of Period	1,122,712	544,777	1,122,712
Supplemental Disclosure of Cash Flow Information:
Interest	143,333	94,832
Income taxes	0	0
Disclosure of non-cash investing and financing activities:
Par value of common stock issued in conjunction with cashless exercise of warrants	29,185	9,782
Issuance of common stock as interest on convertible preferred stock	$ 604,800	$ 347,490

[1] Includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to January 31, 2013" column. See Note 11 - Derivative Warrant Liability.